Not so NICE for Avastin
Executive Summary
The U.K.'s National Institute for Health and Clinical Excellence terminates its review of Roche/Genentech's Avastin (bevacizumab) for first-line metastatic breast cancer because the sponsor failed to submit sufficient evidence, the regulatory body announces June 25. Avastin received approval for a breast cancer indication in the U.S. in February. NICE also stopped its review of Avastin for the first-line treatment of metastatic or recurrent non-small cell lung cancer, another indication approved in the U.S. Review of Bristol-Myers Squibb/ImClone/Merck KGaA's Erbitux (cetuximab) for second-line treatment of colorectal cancer was similarly terminated due to the failure to submit sufficient evidence